London +4420 814 42225
Moscow +7495 543 9194
Kiev +38044 599 2950
info@mrcplast.com

Our Clients

Order Informer

 
Home > News >
 

DuPont and DSM announce joint venture in biomedical materials

September 23/2010

(PRNewswire) -- DuPont (NYSE: DD) and Royal DSM N.V. announce an agreement to form a joint venture to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union regulatory approval. The joint venture will be named Actamax Surgical Materials LLC. Under the joint venture agreement, DuPont and DSM will each share a 50 percent interest.


The joint venture will address the market for surgical sealants, adhesion barriers and tissue adhesives Ц a large and underserved market of more than 100 million annual surgical procedures worldwide. The outcome of many surgical procedures could be positively impacted using next-generation materials under development by the joint venture.


Actamax Surgical Materials LLC will build a comprehensive biomedical product portfolio based on several patent-protected biodegradable hydrogel technologies. The early technology development was completed using DuPont materials science and biotechnology capabilities.  Commercialization will rely on the medical polymer processing and manufacturing capabilities of DSM.

 

mrcplast.com

DuPont and DSM announce joint venture in biomedical materials

DuPont and DSM announce joint venture in biomedical materials

 

 

 

 

 

 

 

 

Tags:No
Category:General News
|
| More

Leave a comment

MRC help

 


 All News   News subscribe